Navigation Links
Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
Date:6/19/2008

Proposals approved by more than 95 percent of votes cast

SEATTLE, June 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) held a Special Meeting in lieu of the Annual Meeting of Shareholders on Thursday, June 19, 2008 at its headquarters in Seattle. At the meeting, shareholders approved all matters with more than 95 percent of votes cast at the meeting voting in favor of each of the items proposed in the Company's Proxy Statement, including the reelection of directors Frederick Telling, M.D. Vartan Gregorian, Ph.D., and James Bianco, M.D. and the ratification of the appointment of Richard Love to the Company's Board of Directors.

Also approved at the meeting were a proposal to increase the number of shares of authorized stock (including an increase in the number of shares of authorized common stock), the reduction of quorum for future shareholder meetings to one-third of the outstanding shares entitled to vote, a proposal to allow the Board of Directors to implement a reverse stock split if and when the Board deems such action appropriate, a proposal to increase the number of shares available for grant under our 2007 Equity Incentive Plan and the ratification of our independent auditors.

During a management presentation, James Bianco, M.D., President and CEO of CTI, also reviewed recent accomplishments of CTI as well as the Company's strategy and potential future milestones that may be achieved over the next year.

Potential Future Milestones:

-- Submission of a supplemental Biologics License Application (sBLA) to the Food and Drug Administration (FDA) for CTI's commercial product, Zevalin(R) (Ibritumomab Tiuxetan), seeking expansion of the label to include use in consolidation therapy for indolent non-Hodgkin's lymphoma (NHL) patients if data obtained by the Company from Bayer Schering's FIT trial prove appropriate for such an application

-- Pending phase III clinical trial results from our ongoing pixantrone trial (BBR 2778), possible submission of a new drug application (NDA) for pixantrone to treat aggressive NHL

-- Expected completion of review of the OPAXIO(TM) (paclitaxel poliglumex, CT-2103) Marketing Authorization Application (MAA) by the European Medicines Agency (EMEA) for use in treating non-small cell lung cancer

"We appreciate the support of our shareholders in approving all items as it is important both from an operational and a strategic perspective as we work to build Cell Therapeutics into a successful commercial organization whose drugs make a profound impact on the daily lives of those with cancer," said James A. Bianco, M.D., President and CEO of CTI. "We believe that the next two years will be transformative for Cell Therapeutics as we have the potential to have multiple approved products in the oncology field. We look forward to updating investors with the progress that we are making on these key milestones."

Additional Information about the Board of Directors

Of the members of CTI's Board of Directors who were reelected or whose appointment was ratified at the shareholder meeting, Drs. Telling and Gregorian and Mr. Love are all independent directors whereas Dr. Bianco is not an independent director due to his position at the Company. Additionally, Dr. Gregorian is a member of the Audit Committee and Chairman of the Nominating and Governance Committee; Dr. Telling is a member of the Audit Committee and Chairman of the Compensation Committee; and Mr. Love is a member of the Compensation Committee. A detailed biography of each member of the Board of Directors can be located at http://www.CellTherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include statements about future sales of Zevalin and the development of OPAXIO and pixantrone which include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with OPAXIO and pixantrone in particular, including, without limitation, the potential failure of these product candidates to prove safe and effective for treatment of non-small cell lung cancer, ovarian cancer, non-Hodgkin's lymphoma, and sarcoma, determinations by regulatory, patent and administrative governmental authorities including but not limited to decisions regarding the review and approval of applications submitted to the FDA or the EMEA, competitive factors, technological developments, costs of developing, producing and selling Zevalin, OPAXIO and pixantrone, the outcome of clinical trial results for ongoing trials of our drugs, including pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Cell Therapeutics, Inc.

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Lindsey Jesch

T : 206.272.4347

F : 206.272.4434

E: media@ctiseattle.com

http://www.CellTherapeutics.com/media.htm

Investors Contact:

Cell Therapeutics, Inc.

Ed Bell

T: 206.272.4345

F: 206.272.4434

E: invest@ctiseattle.com

http://www.CellTherapeutics.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
3. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
4. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
5. Pharmos Issues Letter to Shareholders
6. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
7. YM BIOSCIENCES NOTICE OF ANNUAL MEETING OF SHAREHOLDERS AND NOMINATION OF DIRECTORS
8. YM Biosciences announces adoption of renewed Shareholders Rights Plan
9. Isolagen, Inc. Reports Results of Shareholders Annual Meeting
10. CardioMag Announces Results of 2006 Annual Shareholders Meeting and Board Meeting
11. Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... ... 18, 2017 , ... Allotrope Foundation won the 2017 in ... the Allotrope Framework for commercial use. , The Bio-IT World Best Practices Awards ... the critical role of information technology in modern biomedical research, but also to ...
(Date:7/17/2017)... ... July 17, 2017 , ... ... instruments announced the launch of its new line of Heavy-Duty Orbital Shakers today. ... (both analog and digital) for laboratory applications. These shakers are ideal for ...
(Date:7/16/2017)... ... July 16, 2017 , ... OHAUS Corporation, a leading ... of its new line of Rocking and Waving Shakers today. , Five New ... analog and digital) for laboratory applications in a variety of environmental conditions. Rocking ...
(Date:7/14/2017)... ... July 13, 2017 , ... ... test kit has received US FDA 510 (k) clearance for use on Siemens ... evaluates D-Dimer. Each VALIDATE® D-Dimer kit, prepared using the CLSI EP06-A “equal delta” ...
Breaking Biology Technology:
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
(Date:4/17/2017)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... 2016 Annual Report on Form 10-K on Thursday April 13, 2017 ... ... Investor Relations section of the Company,s website at http://www.nxt-id.com  under ... http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):